Skip to main content

Table 1 Efficacy input parameters

From: Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain

Parameter Palivizumab (SE) No prophylaxis (SE) Distribution in PSA Source
First year (decision tree)
 MA-RSV risk, % 1.9 (0.4) 8.1 (1.6) Beta MAKI trial (2013, Feltes et al. (2003)
 RSV-H risk, % 5.3 (0.9) 9.7 (1.9) Beta Feltes et al. (2003)
 RSV-H: Immediate surgery, % 11.1 (4.0) 11.1 (4.0) Beta Altman et al. (2000)
 RSV-H: No immediate surgery, % 88.9 (17.8) 88.9 (17.8) Beta Altman et al. (2000)
 No surgery, % 39.3 (7.9) 39.3 (7.9) Beta Altman et al. (2000)
 Delayed surgery, % 60.7 (6.5) 60.7 (6.5) Beta Altman et al. (2000)
 Inpatient vs discharged before delayed surgery, % 33 vs 67 (8.1) 33 vs 67 (8.1) Beta Expert opinion*
 Case fatality, % 5.2 (0.9) 5.2 (0.9) Beta Szabo et al. (2013)
 CHD-specific background mortality (first 20 years) age-specific mortality age-specific mortality Fixed Tennant et al. (2010)
 CHD-specific background mortality (beyond 20 years) age-specific mortality age-specific mortality Fixed Diller et al. (2015), National mortality statistics (Spain, 2012)
Proportions of respiratory sequelae (used for transition probability calculations, see Table 2)
MA-RSV:
 Asthma, % 10.3 (1.1) 10.3 (1.1) Beta Stein et al. (1999)
 Allergic sensitization, % 37.4 (3.9) 37.4 (3.9) Beta Sigurs et al. (2010)
RSV-H:
 Asthma, % 32.6 (6.9) 32.6 (6.9) Beta Stein et al. (1999)
 Allergic sensitization, % 43.5 (7.3) 43.5 (7.3) Beta Sigurs et al. (2010)
Other parameter
 Nosocomial infection, % 6.1 (0.6) 6.1 (0.6) Beta Ehlken et al. (2005)
  1. *The SE was assumed to be 20% of the estimated mean
  2. Abbreviations: SE, standard error; PSA, probabilistic sensitivity analysis; RSV, respiratory syncytial virus; MA-RSV, medically attended RSV infection; RSV-H, RSV infection resulting in hospitalization